{"filings":[{"id":1500836,"accession_number":"0001104659-26-081319","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K/A","filed_at":"2026-07-07T20:58:41+00:00","items":["1.01","3.02"],"status":"ready","headline":"GridAI Technologies raises $8.5M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 108,932 shares, pre-funded warrants for 1,742,991 shares, and common warrants for 1,851,923 shares at $4.59 per unit.","Gross proceeds ~$8.5M; 5% at closing, 95% upon SEC registration effectiveness.","Pre-funded warrants exercisable at $0.0001, no expiration; common warrants at $4.47, expire 5 years after registration effective.","Net proceeds for general corporate purposes, including acquisitions, debt repayment, and working capital.","Closing on July 7, 2026; registration rights agreement to file resale registration within 15 days after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1474080,"accession_number":"0001104659-26-080831","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-07-06T21:23:34+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"GridAI raises ~$8.5M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$8.5M from sale of 664,598 shares, 1,187,325 pre-funded warrants, and 1,851,923 common warrants.","Combined purchase price per unit (share or pre-funded warrant + common warrant) is $4.59.","Closing expected July 7, 2026; 5% of proceeds paid at closing, 95% upon SEC effectiveness of resale registration statement.","Net proceeds to be used for general corporate purposes, including acquisitions, debt repayment, and working capital.","Common warrants exercisable at $4.47 per share, expire five years after resale registration effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554316,"accession_number":"0001104659-26-064500","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-05-20T20:06:01+00:00","items":["1.01","9.01"],"status":"ready","headline":"GridAI settles $1.03M debt with $800K cash and 71,482 common shares at $3.25/share","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Settlement resolves $1,032,315 owed under Revolving Loan Agreement; avoids default demand.","Cash payment of $800,000 covers principal ($700K) and $100K interest; 71,482 shares satisfy remaining $232,315 interest.","Shares issued at $3.25 per share (5-day VWAP); lender releases all claims upon closing.","Closing must occur within 10 days; otherwise agreement terminates and debt remains enforceable.","Company had previously disclosed default demand letter from lender on April 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442362,"accession_number":"0001104659-26-061136","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-05-14T20:01:34+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"GridAI Technologies Corp. raises ~$7.8M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$2.54M: 74,000 shares, 1,196,001 pre-funded warrants at $0.00001, and 1,270,001 common warrants at $2.00/unit.","Gross proceeds of ~$5.25M: 87,260 shares, 1,745,199 pre-funded warrants, and 1,832,459 common warrants at $2.865/unit.","Net proceeds for general corporate purposes, working capital, and debt repayment. Closing expected May 18, 2026.","Common warrants exercise prices range $2.56–$2.89 per share, expire five years after resale registration effective date.","Registration rights agreement: file resale registration statement within 15 days after closing; 80% of $5.25M proceeds deferred until SEC effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94028,"accession_number":"0001104659-26-055628","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GridAI regains Nasdaq compliance after filing delinquent 2025 10-K","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed its 2025 Form 10-K on May 1, 2026, which was past the original due date.","Received deficiency letter on April 22, 2026 for failure to file periodic reports.","Nasdaq confirmed on May 4, 2026 that Company has regained compliance.","The matter is closed; no further action required per Nasdaq notification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94027,"accession_number":"0001104659-26-050499","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"GridAI receives Nasdaq notice for late 10-K filing; 60-day compliance plan deadline","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency letter on April 22, 2026 for failing to file FY2025 10-K by deadline.","Must submit compliance plan by June 22, 2026; Nasdaq may grant extension to October 12, 2026.","Delay attributed to complex accounting review of recent Grid AI Corp acquisition.","If plan rejected, company can appeal to Nasdaq hearings panel; delisting risk remains.","Company intends to file 10-K as soon as possible and regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94026,"accession_number":"0001104659-26-048549","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"GridAI receives loan default demand for $1.01M from lender","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Demand letter received April 1, 2026, asserts default on $700,000 principal under Revolving Loan Agreement.","Total demanded sum of $1,014,675 includes principal, interest, and a 20% default penalty.","Company is evaluating the matter and is in active discussions with the lender."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94025,"accession_number":"0001104659-26-042177","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K/A","filed_at":"2026-04-13T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"GridAI Technologies provides acquired GridAI audited financials: $3.3M net loss, going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GridAI net loss of $5.3M for inception-to-Sept 2025; $3.3M loss attributable to GridAI on $139K revenue.","Total assets $2.2M vs current liabilities $8.7M; working capital deficit of $7.6M.","Cash only $333K; $7.0M deferred consideration payable due from GridAI's AMPx acquisition.","Auditor flags substantial doubt about going concern; negative equity of $6.5M.","GridAI acquired 51% of AMPx UK Holdings on Feb 28, 2025; deal closed Sept 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106090,"accession_number":"0001104659-26-001755","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"GridAI completes rescission of ImmunogenX acquisition, removes $83.2M in assets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rescission completed Dec 31, 2025; Immuno LLC is no longer a subsidiary.","Pro forma total assets as of Sep 30, 2025: $52.2M (down from $135.4M).","Pro forma net loss from continuing ops for nine months ended Sep 30, 2025: $2.59M, diluted EPS -$1.77.","Removed 11,777,418 shares of Series G Preferred Stock issued to IMGX as part of rescission.","Pro forma net loss from continuing ops for year ended Dec 31, 2024: $15.62M, diluted EPS -$4.62."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122384,"accession_number":"0001104659-25-124213","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"GridAI appoints Jason D. Sawyer as permanent CEO; new consulting agreement with $25k/mo base, RSUs, and severance terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason D. Sawyer appointed permanent CEO effective Dec 19, 2025, transitioning from interim role.","Amended consulting agreement with Access Alternative Group for CEO services; initial 2-year term renewable yearly.","Base cash compensation $25,000/month retroactive to Oct 1, 2025; plus $20,000/quarter for Nasdaq compliance.","One-time payment of $150,000 + 400,000 shares upon shareholder approval of Grid AI Corp acquisition.","RSUs for 1,000,000 shares vesting quarterly in 2026; accelerate on termination without cause or change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122383,"accession_number":"0001104659-25-118524","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["1.01","5.02","5.03","8.01","9.01"],"status":"ready","headline":"GridAI director Corbett resigns citing governance concerns; ticker changes to GRDX","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Eric Corbett resigned due to disagreements over financial statement accuracy, GRID AI due diligence, and press release quality.","Director Richard Paolone also resigned; received $500K separation agreement and legal fees.","Name changed to GridAI Technologies Corp and ticker to GRDX effective Dec 1, 2025.","Corbett's letter flagged potentially inaccurate financial statements and misleading press releases disseminated to the market.","Name change follows acquisition of GRID AI Corp; board committees reconstituted with Borkowski, Uppal, Pursglove."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122382,"accession_number":"0001104659-25-107715","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GridAI stockholders waive board appointment rights pending shareholder approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GridAI stockholders waived right to appoint two directors to Entero board until shareholder vote.","Waiver relates to Section 5.09 of the Share Exchange Agreement dated Sept 30, 2025.","The original agreement was filed on Form 8-K on Oct 6, 2025.","Company must hold a shareholder meeting to approve the appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122381,"accession_number":"0001104659-25-104917","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq confirms Entero Therapeutics regains compliance with equity rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter dated Oct 28, 2025 confirms company meets $2.5M minimum stockholders' equity requirement.","Company previously reported negative equity of ($3.87M) in 10-K; received extension until Oct 8, 2025.","Compliance achieved via share exchange with GridAI Corp, disclosed in Oct 6, 2025 8-K.","Nasdaq warned that failure to maintain compliance in next periodic report may trigger delisting proceedings.","Company's stock (ENTO) continues trading on Nasdaq Capital Market without immediate delisting risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122380,"accession_number":"0001104659-25-101519","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Entero Therapeutics enters up to $5M securities purchase agreement with initial $500k closing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial closing of $500k non-interest bearing promissory note due one year and one day from issuance.","Warrants to purchase up to 1.52M shares at $2.50/share, exercisable after stockholder approval.","Company may hold subsequent closings for remaining $4.5M through Final Closing Date.","Proceeds for general corporate purposes, including working capital and potential acquisitions.","Note is not convertible; maturity may be extended in one-year increments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122379,"accession_number":"0001104659-25-097138","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["1.01","2.01","3.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Entero Therapeutics acquires GridAI in share exchange; former GridAI holders to own 82.5% of diluted ENTO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of GridAI for 424,348 common shares (19.99% of outstanding) and 38,801,546 Series H convertible shares.","Upon conversion (subject to shareholder approval), former GridAI stockholders will own 82.5% of ENTO on a fully diluted basis.","GridAI is a grid-edge AI platform managing behind-the-meter assets; over $50M invested since 2019.","ENTO must raise at least $3M in gross proceeds within 30 days post-closing and maintain $2M cash minimum.","Former GridAI shareholders get right to designate 2 directors initially, eventually 5 of 7 board seats."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139091,"accession_number":"0001104659-25-089562","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Entero Therapeutics appoints Jason D. Sawyer as Interim CEO under consulting agreement at $12,500/month","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason D. Sawyer appointed Interim CEO via consulting agreement with Access Alternative Group S.A., effective Sept 4, 2025.","Compensation set at $12,500 per month; agreement renewable month-to-month at Company's discretion.","Company to indemnify Sawyer as CEO to fullest extent under Delaware law; D&O insurance maintained.","Prior interim CEO appointment disclosed Sept 9; formal consulting agreement entered Sept 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139090,"accession_number":"0001104659-25-088663","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.02","5.02","9.01"],"status":"ready","headline":"Entero Therapeutics replaces Interim CEO; appoints Jason D. Sawyer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Joel Paolone terminated as Interim CEO and Chairman, effective Sept 3, 2025, without cause.","Paolone remains as director; consulting agreement terminated with payment in lieu of notice.","Jason D. Sawyer appointed Interim CEO effective Sept 4, 2025; continues as director.","Sawyer has 32-year investment background; currently Head of Finance & M&A at Quantum BioPharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139089,"accession_number":"0001104659-25-079322","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Entero Therapeutics announces 1-for-3 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1-for-3 effective 12:01 a.m. ET on August 18, 2025.","Outstanding shares reduce from ~4.77 million to ~1.59 million; no fractional shares issued.","Split intended to raise bid price above $1.00 to satisfy Nasdaq Listing Rule 5550(a)(2).","Trading symbol remains ENTO; new CUSIP is 33749P507.","Interim CEO Richard Paolone states split is necessary to maintain Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139088,"accession_number":"0001104659-25-075970","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Entero Therapeutics raises $3M in private placement; appoints two new directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $3.0M from sale of pre-funded warrants and common warrants priced at $0.6149 per unit.","$1M paid at closing (Aug 11, 2025); remaining $2M due upon effectiveness of resale registration statement.","Pre-funded warrants exercisable at $0.00001; common warrants at $0.3649, expire 5 years after registration effective.","Geordan Pursglove and Jason Sawyer appointed to Board effective Aug 11, 2025; each receives $2,500/month cash retainer.","Net proceeds for general corporate purposes and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139087,"accession_number":"0001104659-25-068362","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Entero Therapeutics amends rescission agreement adding accredited investor reps from ImmunogenX shareholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment adds Section 5(f) to Rescission Agreement, requiring each shareholder to be an accredited investor under Rule 501 of Regulation D.","Shareholders also represent they have no need for liquidity, have evaluated investment risks, and are acquiring Membership Units for own account.","Amendment effective July 15, 2025; parties include Entero Therapeutics, ImmunogenX LLC, and former ImmunogenX shareholders.","Original Rescission Agreement, disclosed March 25, 2025, unwound the merger between Entero and ImmunogenX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139086,"accession_number":"0001104659-25-066418","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Entero Therapeutics regains Nasdaq annual meeting compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter confirming compliance with Listing Rule 5620(a) after holding Annual Meeting on June 30, 2025.","Matter is now closed; no further action required from Nasdaq.","Company had previously reported the meeting in a Form 8-K filed July 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139085,"accession_number":"0001104659-25-065274","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Entero Therapeutics shareholders approve reverse stock split authorization at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders authorized a reverse stock split at ratio between 1:2 and 1:20, with board discretion to set ratio within one year.","Re-elected directors Edward J. Borkowski, Richard Paolone, Eric Corbett, Manpreet Uppal, and Jack Syage.","Ratified Machias Gini & O'Connell LLP as independent auditor for fiscal year ending December 31, 2025.","Advisory vote on named executive officer compensation passed with 415,176 for, 77,434 against (excluding broker non-votes).","All five proposals were approved; broker non-votes totaled 1,328,218 on director elections and advisory compensation vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156598,"accession_number":"0001104659-25-064144","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq grants Entero Therapeutics extension to Oct 8, 2025 to meet minimum equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received Nasdaq extension letter on June 25, 2025; deadline to regain compliance is October 8, 2025.","Must meet Nasdaq Rule 5550(b)(1) minimum stockholders' equity of $2.5 million.","As of Dec 31, 2024, stockholders' equity was negative $3.88 million, triggering the deficiency.","Failure to regain compliance may result in delisting, but appeal to a Nasdaq Hearing Panel is permitted.","No assurance that compliance will be achieved or listing maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156597,"accession_number":"0001104659-25-048544","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["1.01","2.03","5.08","9.01"],"status":"ready","headline":"Entero Therapeutics subsidiary settles litigation, restructures $7.9M debt with $5.5M payment and new revolving loan","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["ImmunogenX subsidiary settled lawsuit with Mattress Liquidators; guarantors paid $5.5M of ~$7.9M owed on Apr 9, 2025.","New revolving loan of $2.44M to ImmunogenX matures Apr 9, 2028; security interest in subsidiary released.","Lawsuit to be dismissed with prejudice; ImmunogenX responsible for ~$62,000 in plaintiff's legal fees.","Annual meeting June 27, 2025; stockholder proposals/director nominations due by May 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156596,"accession_number":"0001104659-25-034689","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Entero Therapeutics receives Nasdaq deficiency notice for stockholders' equity shortfall","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders' equity of ($3,876,738) as of Dec 31, 2024, well below Nasdaq's $2.5M minimum.","Company also failed alternative compliance standards for market value or net income.","Must submit compliance plan by May 26, 2025; Nasdaq may grant extension to Oct 8, 2025.","Company intends to submit a plan, but no assurance of acceptance or regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175024,"accession_number":"0001104659-25-027770","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Entero Therapeutics rescinds 2024 ImmunogenX merger, retains $695K AP; names new CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rescission Agreement with ImmunogenX LLC signed March 24, 2025; unwinds the March 2024 merger.","Closing conditions include shareholder approval by June 30, 2025, lender consent, and resignation of director Jack Syage.","Company retains ~$695,000 of ImmunogenX accounts payable; ImmunogenX remains responsible for ~$9.28M secured debt.","Anna Skowron appointed CFO effective March 3, 2025; brings 14+ years of accounting and financial reporting experience.","CEO states rescission strengthens balance sheet and refocuses value creation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175023,"accession_number":"0001104659-25-021728","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["1.01","5.02","3.01","9.01"],"status":"ready","headline":"Nasdaq extends Entero bid price compliance to Sept 1, 2025; CFO resigns, Skowron named CFO","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted extension until Sept 1, 2025 to regain $1.00 minimum bid price compliance.","CFO Sarah Romano resigned effective March 7; Anna Skowron appointed CFO at $8,333/month.","CEO Richard Paolone's consulting agreement formalized, paying $12,500/month retroactive to Feb 12.","Nasdaq extended annual meeting compliance deadline to June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175022,"accession_number":"0001104659-25-014165","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Entero Therapeutics terminates CEO James Sapirstein, appoints Richard Paolone as interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Sapirstein terminated as CEO without cause effective February 12, 2025.","Richard Paolone appointed interim CEO and Chairman, effective immediately.","Paolone is a Toronto securities lawyer with board seats at multiple public companies.","Paolone ceases to be independent director; Eric Corbett joins audit, governance, and compensation committees.","Paolone's compensation as interim CEO to be determined at a later date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175021,"accession_number":"0001104659-25-010132","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["1.01","2.03","5.01","5.02","9.01"],"status":"ready","headline":"Entero Therapeutics enters $2M loan at 18%; lender gains board control, replaces three directors","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving loan up to $2M from 1396974 BC Ltd.; initial $550K drawn Jan 31, 2025 at 18% interest, due Jan 31, 2026.","Three directors resigned Feb 3 (Ramdeen, Riddell, Sapirstein); three lender nominees appointed (Uppal, Niu, Paolone) giving board majority to lender.","Alson Niu resigned Feb 5; replaced by Eric Corbett as director.","Loan requires best efforts to complete a $5M+ qualified public equity offering; S-1 must be filed within 45 days.","Company must refrain from repaying other debt or making payments >$25k without board approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175020,"accession_number":"0001104659-25-003048","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Entero Therapeutics receives Nasdaq notice for missing 2024 annual meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Jan 7, 2025 for non-compliance with Nasdaq Listing Rule 5620(a) due to no 2024 annual meeting.","Company has until Feb 21, 2025 to submit a compliance plan; extension possible to June 30, 2025.","Intends to hold annual meeting as soon as practicable and will file a proxy statement.","Notice has no immediate effect on listing or trading of common stock (ENTO).","Failure to regain compliance may lead to delisting; company can appeal to Nasdaq hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191987,"accession_number":"0001104659-24-123742","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"Entero Therapeutics subsidiary receives default notice; $7.4M debt accelerated","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["ImmunogenX received default notice on Nov 21, 2024 from lender Mattress Liquidators, Inc., accelerating ~$7.4M in obligations.","Company disputes default regarding missing separate financials, noting consolidated reports are filed with SEC.","Cross-default may trigger stockholder notes with Jack Syage and Peter Felker, potentially due immediately.","Firm paused development, reduced headcount, and is exploring strategic alternatives including merger, sale, or wind-down.","No assurance of raising capital or restructuring debt; possible U.S. Bankruptcy Code protection if efforts fail."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191986,"accession_number":"0001104659-24-117204","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Entero Therapeutics to reverse-merge with Journey Therapeutics, issuing 99% equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Entero (ENTO) signs binding term sheet to acquire all Journey equity; Journey holders get 99% of combined company.","Post-close, Journey CEO Henry Ji to become CEO and Chairman of the combined company.","Conditions include $5M equity financing, S-4 effectiveness, Nasdaq listing, and ENTO stockholder approval.","Combined entity will focus on Journey's NIC platform for oncology and Entero's GI pipeline (latiglutenase, adrulipase, capeserod).","NIC platform licensed from Mayo Clinic; early Phase 1 data in ovarian/endometrial cancer and non-Hodgkin's lymphoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208452,"accession_number":"0001104659-24-098971","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Entero Therapeutics receives Nasdaq bid price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Entero on Sept 6, 2024 that common stock failed minimum $1.00 bid price for 30 consecutive business days.","Company has until March 5, 2025 to regain compliance by closing at $1.00 for 10 consecutive business days.","If not compliant, Nasdaq may grant second 180-day period if other listing standards met; otherwise delisting possible.","Company intends to monitor bid price and seek compliance; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208451,"accession_number":"0001104659-24-098369","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Entero Therapeutics signs LOI to license clinical trial compliance platform from DataVault Holdings","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Binding LOI for exclusive worldwide license to QOLPOM and FotoDigm clinical trial software from DataVault Holdings.","Consideration: $250,000 in convertible preferred shares priced at 180% of 5-day VWAP plus single-digit royalties on net sales.","Deal contingent on Entero securing at least $500,000 strategic investment; target up to $3M.","License intended to support Entero's planned Phase 3 latiglutenase trial for celiac disease and other GI indications.","Right of first refusal to fully acquire the assets; closing targeted by end of September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208450,"accession_number":"0001104659-24-096362","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Entero Therapeutics subsidiary receives default suspension, but no waiver","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["On August 29, 2024, ImmunogenX received letter from Lender Mattress Liquidators suspending MAE Default under Credit Agreement.","Original Notice of Default was received on August 2, 2024, alleging Material Adverse Effect and accelerating all obligations.","Lender's suspension is not a waiver; all rights regarding enforcement of MAE Default are expressly reserved.","No principal amount or financial impact disclosed in filing; discussions are ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208449,"accession_number":"0001104659-24-094936","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Entero Therapeutics appoints Machias Gini & O'Connell LLP as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed MGO as independent registered public accounting firm effective August 27, 2024, subject to stockholder ratification.","No consultations with MGO on accounting principles or disagreements during fiscal 2022-2023 and interim 2024.","MGO furnished a letter to the SEC, filed as Exhibit 16.1, regarding the disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208448,"accession_number":"0001104659-24-092491","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Entero Therapeutics receives Nasdaq non-compliance notice for late Form 10-Q filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on Aug 21, 2024, for failure to timely file Q2 2024 Form 10-Q.","Company has 60 days (until Oct 21, 2024) to submit compliance plan; possible extension to Feb 17, 2025.","Forvis Mazars resigned as auditor on Aug 9, 2024; company seeking new independent accounting firm.","Notice has no immediate effect on Nasdaq listing, but delisting risk if compliance not regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208447,"accession_number":"0001104659-24-092061","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Board member Khosla resigns; Ramdeen appointed to Audit Committee; CEO Sapirstein gets post-termination medical benefits","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chaitan Khosla resigned from Board effective August 16, 2024.","Timothy Ramdeen appointed to Audit Committee on August 21, 2024 to fill the vacancy.","Independent directors approved payment of CEO James Sapirstein's post-employment medical insurance premiums for six months.","Payment maintains coverage after termination of Sapirstein's employment agreement on August 2, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208446,"accession_number":"0001104659-24-089923","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"Entero Therapeutics' auditor Forvis Mazars resigns over financial reporting reliability concerns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Forvis Mazars resigned as independent auditor on Aug 9, 2024, citing belief that cost reduction measures prevent reliable financial reporting.","Company disagrees with auditor's belief and states it has sufficient management and governance.","Forvis Mazars was appointed on June 1, 2024 and never issued audit reports for fiscal years 2022 and 2023.","Board appointed Timothy R. Ramdeen as new director; he brings life science investment experience.","Board filled audit committee vacancies: Chaitan Khosla and Alastair Riddell appointed, Edward Borkowski named Audit Chair and Compensation Committee Chair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208445,"accession_number":"0001104659-24-086824","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.04","3.01","5.02","8.01","9.01"],"status":"ready","headline":"Entero Therapeutics faces $7M debt acceleration, board resignations, workforce cuts, R&D pause","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ImmunogenX subsidiary received default notice accelerating $6,997,583 in obligations under Credit Agreement.","Directors Charles Casamento and Terry Coelho resigned Aug 2; audit committee now non-compliant with Nasdaq Rule 5605(c)(2).","CEO James Sapirstein and President Jack Syage terminated; Sapirstein becomes consultant at $400/hour for 6 months.","Company terminated all non-essential employees, vacated Boca Raton office, and paused non-essential R&D activities.","Exploring strategic alternatives including capital raising, restructuring debt, and other options to maximize stakeholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208444,"accession_number":"0001104659-24-084206","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Entero Therapeutics provides latiglutenase Phase 3 plan, FDA meetings, $1.9M raise","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submits Type D requests to FDA to streamline Phase 3 trial cohorts from three to two (1200 mg and placebo).","Second Type D request seeks FDA agreement on histology secondary endpoints based on Phase 2 results.","Raised $1.9 million in gross proceeds from a small financing to support Phase 3 trial initiation.","Consolidated bi-coastal operations into Boca Raton HQ to reduce overhead costs.","CEO James Sapirstein reaffirms goal to start pivotal Phase 3 trial for latiglutenase in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208443,"accession_number":"0001104659-24-081888","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Entero Therapeutics CSO Jack Syage resigns; salary cut to $66,560 as cost reduction","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jack Syage resigned as Chief Scientific Officer effective July 17, 2024, will remain President and Board member.","Resignation is part of cost reduction measures, not due to any disagreement with company policies.","Annual base salary reduced to $66,560, effective July 1, 2024; other compensation terms unchanged.","CEO James Sapirstein signed the filing on July 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208442,"accession_number":"0001104659-24-079101","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Entero Therapeutics raises $1.9M via warrant exercise inducement; issues new warrants for 3.5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$1.9M from cash exercise of 1,762,674 existing warrants at a reduced price of $1.09 per share.","In exchange, the company issued new inducement warrants to purchase up to 3,525,348 shares at $1.09, exercisable for 5 years from stockholder approval.","Roth Capital Partners acted as financial advisor, receiving ~$96,000 in fees plus expense reimbursement.","Company agreed to file a resale registration statement for the new warrant shares by July 25, 2024.","Transaction structured as an at-market warrant inducement under Nasdaq rules; no variable rate transactions until July 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226128,"accession_number":"0001104659-24-073418","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Entero Therapeutics transitions COO Jack Syage to Chief Scientific Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack Syage, previously President and COO, appointed Chief Scientific Officer effective June 17, 2024.","Syage retains President title and reports to CEO James Sapirstein; compensation unchanged.","Chief Operating Officer role vacated; no replacement named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226127,"accession_number":"0001104659-24-068733","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Entero Therapeutics replaces auditor Mazars with Forvis Mazars effective June 1, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mazars USA LLP resigned after its partners and employees joined FORVIS LLP; the combined firm is now Forvis Mazars LLP.","No adverse opinions, disagreements, or reportable events occurred in fiscal years 2022 or 2023 during Mazars' tenure.","Audit committee appointed Forvis Mazars as new independent registered public accounting firm, subject to stockholder ratification.","Mazars' letter to the SEC regarding the change is filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226126,"accession_number":"0001104659-24-066738","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K/A","filed_at":"2024-05-30T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Entero Therapeutics files Q1 2024 pro forma statements post-ImmunogenX merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment adds unaudited pro forma combined statement of operations for three months ended March 31, 2024.","Pro forma combined net loss applicable to common shareholders: $1,894,119.","Pro forma basic loss per share: $1.08; diluted loss per share: $1.08.","Merger with ImmunogenX closed March 13, 2024; Entero is accounting acquirer.","No changes to merger terms or business operations; filing purely supplemental."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226131,"accession_number":"0001104659-24-062263","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.03","7.01","8.01","9.01"],"status":"ready","headline":"First Wave BioPharma changes name to Entero Therapeutics; ticker to ENTO effective May 17","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from First Wave BioPharma to Entero Therapeutics effective May 17, 2024.","Nasdaq ticker symbol changes from FWBI to ENTO at market open on May 17.","Rebranding follows recent business combination with ImmunogenX, reflecting GI-focused pipeline.","Lead asset latiglutenase for celiac disease; Phase 3 trial expected to begin early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226130,"accession_number":"0001104659-24-060689","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"First Wave BioPharma raises ~$1.1M in registered direct offering priced at $2.95/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds expected ~$1.1M; net proceeds ~$0.9M after agent fees.","Offering includes 366,000 shares/pre-funded warrants at $2.95 and warrants for 732,000 shares at $2.70.","Warrants are immediately exercisable, 6-year term, exercise price $2.70.","Proceeds to be used for working capital and general corporate purposes.","Closing expected on or about May 14, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226129,"accession_number":"0001104659-24-058866","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K/A","filed_at":"2024-05-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"ImmunogenX reports net loss of $8.86M in 2023; auditor cites going concern doubts","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net loss for 2023 was $8.86M, compared to $3.62M in 2022 and $1.66M in 2021.","Total assets of $4.1M vs. total liabilities of $18.33M as of Dec 31, 2023, resulting in stockholders' deficit of $14.23M.","Cash and cash equivalents only $251k as of Dec 31, 2023; auditor expressed substantial doubt about going concern.","Pre-revenue clinical-stage biotherapeutics company focused on celiac disease treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245211,"accession_number":"0001104659-24-037932","cik":1604191,"company_name":"GridAI Technologies Corp.","ticker":"GRDX","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq issues reprimand to First Wave BioPharma for shareholder approval lapse; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On March 19, 2024, Nasdaq issued a Letter of Reprimand for the July 2023 offering of 610k shares and warrants at $0.64/share.","The offering was deemed not a public offering under Rule 5635(d) because one investor bought a predominant portion; shareholder approval was required but not obtained.","The Company obtained shareholder ratification on December 12, 2023, as remedial action.","Nasdaq noted the failure was inadvertent, no prior pattern of non-compliance, and considers the matter closed.","No delisting or further sanctions imposed; the Company remains listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31868260.253164552,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-03-22T23:59:59+00:00|245211"}